07.11.2017
- Sanofi is pursuing another US competitor for alleged breach of the patent for its top-selling diabetes drug insulin glargine (branded as Lantus and Lantus SoloStar), which together...
11.08.2017
- Sanofi has sued US Merck, alleging infringement of two patents related to an insulin drug. The French drugmaker said the action was triggered by a notification received from Merck...
04.04.2016
- Analysts love looking into the future, particularly when it comes to big pharma’s prospect for growth and earnings. The industry experts of Morningstar see slowing patent losses...
29.04.2015
- The European Commission has granted marketing authorization in Europe for Sanofi's Toujeo, a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus...
30.06.2014
- The European Medicine Agency (EMA) has recommended approval of Abasria, Eli Lilly's biosimilar version of Sanofi's insulin glargine sold as Lantus. This means that the French...
01.02.2014
- Paris-based pharmaceuticals producer Sanofi has filed a patent infringement suit against U.S. drugmaker Eli Lilly, claiming that its U.S. rival infringed four of its patents for...
02.05.2013
- Sanofi is stepping up the development of a fixed combination of diabetes treatments Lantus and Lyxumia to sidestep an earlier setback with a similar pen device and take advantage...
08.06.2012
- Danish drugmaker Novo Nordisk , the world's biggest insulin maker, said on Friday that U.S. health regulators had extended their review of its new ultra-long-acting insulin Tresiba...
